263 related articles for article (PubMed ID: 30344922)
21. Remodels the Immunosuppressive Tumor Microenvironment by Combination of Bacillus Calmette-Guérin and Anti-PD-L1 in an Orthotopic Triple-Negative Breast Cancer Mouse Model.
Lu Y; Huang X; Liu X; He Y; Hu Z; Xu W; Cao G; He W
Onco Targets Ther; 2021; 14():2247-2258. PubMed ID: 33833524
[TBL] [Abstract][Full Text] [Related]
22.
Su F; Liu M; Zhang W; Tang M; Zhang J; Li H; Zou L; Zhang R; Liu Y; Li L; Ma J; Zhang Y; Chen M; Xiao F
Front Oncol; 2022; 12():842182. PubMed ID: 35311085
[TBL] [Abstract][Full Text] [Related]
23. Maintenance Therapy with 3-monthly Bacillus Calmette-Guérin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non-muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013.
Martínez-Piñeiro L; Portillo JA; Fernández JM; Zabala JA; Cadierno I; Moyano JL; Solsona E; Unda M; Beardo P; Rodríguez-Molina J; Chantada V; Palou J; Muntañola P; Alonso Dorrego JM; Pérez-Garcia FJ; Silva JM; Chesa N; Montesinos M; Ojea A; Madero R; Martínez-Piñeiro JA
Eur Urol; 2015 Aug; 68(2):256-62. PubMed ID: 25794457
[TBL] [Abstract][Full Text] [Related]
24. Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: A retrospective study.
Le Goux C; Damotte D; Vacher S; Sibony M; Delongchamps NB; Schnitzler A; Terris B; Zerbib M; Bieche I; Pignot G
Urol Oncol; 2017 May; 35(5):257-263. PubMed ID: 28291636
[TBL] [Abstract][Full Text] [Related]
25. Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Guérin therapy in bladder cancer.
Pichler R; Fritz J; Zavadil C; Schäfer G; Culig Z; Brunner A
Oncotarget; 2016 Jun; 7(26):39916-39930. PubMed ID: 27221038
[TBL] [Abstract][Full Text] [Related]
26. FGFBP1 as a potential biomarker predicting bacillus Calmette-Guérin response in bladder cancer.
Li F; Zhang H; Wang Y; Yao Z; Xie K; Mo Q; Fan Q; Hou L; Deng F; Tan W
Front Immunol; 2022; 13():954836. PubMed ID: 36119059
[TBL] [Abstract][Full Text] [Related]
27. Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer.
Lamm D; Brausi M; O'Donnell MA; Witjes JA
Urol Oncol; 2014 Jan; 32(1):35.e21-30. PubMed ID: 23628309
[TBL] [Abstract][Full Text] [Related]
28. Bacillus Calmette-Guérin Induces PD-L1 Expression on Antigen-Presenting Cells via Autocrine and Paracrine Interleukin-STAT3 Circuits.
Copland A; Sparrow A; Hart P; Diogo GR; Paul M; Azuma M; Reljic R
Sci Rep; 2019 Mar; 9(1):3655. PubMed ID: 30842561
[TBL] [Abstract][Full Text] [Related]
29. Effects of intravesical therapy with platelet-rich plasma (PRP) and Bacillus Calmette-Guérin (BCG) in non-muscle invasive bladder cancer.
Dias LP; Luzo ÂCM; Volpe BB; Durán M; Galdames SEM; Ferreira LAB; Durán N; Fávaro WJ
Tissue Cell; 2018 Jun; 52():17-27. PubMed ID: 29857824
[TBL] [Abstract][Full Text] [Related]
30. Bacillus Calmette-Guérin Immunotherapy for Cancer.
Cardillo F; Bonfim M; da Silva Vasconcelos Sousa P; Mengel J; Ribeiro Castello-Branco LR; Pinho RT
Vaccines (Basel); 2021 May; 9(5):. PubMed ID: 34062708
[TBL] [Abstract][Full Text] [Related]
31. Intravesical Bacillus Calmette-Guérin Versus Combination of Epirubicin and Interferon-α2a in Reducing Recurrence of Non-Muscle-invasive Bladder Carcinoma: FinnBladder-6 Study.
Marttila T; Järvinen R; Liukkonen T; Rintala E; Boström P; Seppänen M; Tammela T; Hellström P; Aaltomaa S; Leskinen M; Raitanen M; Kaasinen E;
Eur Urol; 2016 Aug; 70(2):341-7. PubMed ID: 27085624
[TBL] [Abstract][Full Text] [Related]
32. From Interferon to Checkpoint Inhibition Therapy-A Systematic Review of New Immune-Modulating Agents in Bacillus Calmette-Guérin (BCG) Refractory Non-Muscle-Invasive Bladder Cancer (NMIBC).
Deininger S; Törzsök P; Mitterberger M; Pallauf M; Oswald D; Deininger C; Lusuardi L
Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158964
[TBL] [Abstract][Full Text] [Related]
33. Intravesical bacillus Calmette-Guerin immunotherapy after previous prostate radiotherapy for high-grade non-muscle-invasive bladder cancer.
Rao MV; Ellimoottil C; Sondej T; Flanigan RC; Quek ML
Urol Oncol; 2013 Aug; 31(6):857-61. PubMed ID: 21868262
[TBL] [Abstract][Full Text] [Related]
34. Sequential combination of mitomycin C plus bacillus Calmette-Guérin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomized prospective trial.
Solsona E; Madero R; Chantada V; Fernandez JM; Zabala JA; Portillo JA; Alonso JM; Astobieta A; Unda M; Martinez-Piñeiro L; Rabadan M; Ojea A; Rodriguez-Molina J; Beardo P; Muntañola P; Gomez M; Montesinos M; Martinez Piñeiro JA;
Eur Urol; 2015 Mar; 67(3):508-16. PubMed ID: 25301758
[TBL] [Abstract][Full Text] [Related]
35. Combined assessment of peritumoral Th1/Th2 polarization and peripheral immunity as a new biomarker in the prediction of BCG response in patients with high-risk NMIBC.
Martínez R; Tapia G; De Muga S; Hernández A; Cao MG; Teixidó C; Urrea V; García E; Pedreño-López S; Ibarz L; Blanco J; Clotet B; Cabrera C
Oncoimmunology; 2019; 8(8):1602460. PubMed ID: 31413912
[TBL] [Abstract][Full Text] [Related]
36. Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.
Farina MS; Lundgren KT; Bellmunt J
Drugs; 2017 Jul; 77(10):1077-1089. PubMed ID: 28493171
[TBL] [Abstract][Full Text] [Related]
37. The role of bacillus Calmette-Guérin in the treatment of non-muscle-invasive bladder cancer.
Gontero P; Bohle A; Malmstrom PU; O'Donnell MA; Oderda M; Sylvester R; Witjes F
Eur Urol; 2010 Mar; 57(3):410-29. PubMed ID: 19969411
[TBL] [Abstract][Full Text] [Related]
38. Emerging trends of BCG immunotherapy for bladder cancer in last decade: a bibliometric and visualization analysis.
Chen X; He F; Zhang W; Fu Y; Cao Z
Front Oncol; 2023; 13():1092969. PubMed ID: 37124495
[TBL] [Abstract][Full Text] [Related]
39. Epigenetic changes associated with Bacillus Calmette-Guerin (BCG) treatment in bladder cancer.
Picard LC; Rich FJ; Kenwright DN; Stevens AJ
Biochim Biophys Acta Rev Cancer; 2024 May; 1879(5):189123. PubMed ID: 38806074
[TBL] [Abstract][Full Text] [Related]
40. Effect of different Bacillus Calmette-Guerin substrains on growth inhibition of T24 bladder cancer cells and cytokines secretion by BCG activated peripheral blood mononuclear cells of PBMCs.
Janaszek-Seydlitz W; Prygiel M; Bucholc B; Wiatrzyk A; Czajka U; Górska P; Soliwoda U
Adv Clin Exp Med; 2014; 23(6):877-84. PubMed ID: 25618112
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
